M A Kirchin Selected Research

gadobenic acid (gadobenate dimeglumine)

9/2015	The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).
4/2015	Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?
8/2004	A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours.
3/2002	Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine.
12/2001	Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.
11/2001	Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation.
10/2001	Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.
2/2001	Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage.
6/2000	Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.
1/2000	Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M A Kirchin Research Topics

Disease

4	Body Weight (Weight, Body) 09/2015 - 11/2001
3	Brain Neoplasms (Brain Tumor) 09/2015 - 03/2002
3	Neoplasm Metastasis (Metastasis) 08/2004 - 02/2001
2	Neoplasms (Cancer) 10/2001 - 02/2001
1	Exsanguination 04/2015
1	Nephrogenic Fibrosing Dermopathy 04/2015
1	Glioma (Gliomas) 08/2004
1	Focal Nodular Hyperplasia 12/2001
1	Liver Neoplasms (Liver Cancer) 10/2001
1	Hypersensitivity (Allergy) 02/2001
1	Pain (Aches) 02/2001
1	Thrombosis (Thrombus) 02/2001
1	Acquired Immunodeficiency Syndrome (AIDS) 06/2000
1	Metaplasia 01/2000
1	Hepatocellular Carcinoma (Hepatoma) 01/2000
1	Liver Failure 01/2000

Drug/Important Bio-Agent (IBA)

10	gadobenic acid (gadobenate dimeglumine)FDA Link 09/2015 - 01/2000
3	Contrast MediaIBA 01/2015 - 02/2001
2	gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetateIBA 09/2015 - 08/2004
2	gadoterate meglumineIBA 09/2015 - 08/2004
1	gadoteridol (Prohance)FDA Link 01/2015
1	gadobutrolIBA 01/2015
1	GadoliniumIBA 01/2015
1	Ethiodized Oil (Ethiodol)FDA Link 10/2001
1	iodixanol (Visipaque)FDA Link 02/2001
1	iopentolIBA 02/2001
1	iomeprolIBA 02/2001
1	Ioxaglic Acid (Ioxaglate Meglumine)FDA Link 02/2001

Therapy/Procedure

2	Injections 03/2002 - 11/2001
1	Intra-Arterial Injections 02/2001
1	Percutaneous Coronary Intervention 02/2001